Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS)
This study enrolls adults with MS. The purpose of this study is to learn which therapy is most effective for people with MS.
You will be in this study for about 3 years. You will have neurological evaluations, undergo MRIs, complete questionnaires and, if you chose to, have blood samples collected. In this study you will choose, along with your neurologist, to start one of two treatment approaches: “escalation approach” or “early highly effective treatment” (EHT) or you will be followed in an observational study (a study where patients and physicians freely make treatment decisions). An "escalation approach" means starting a drug that is considered safe but that is modestly likely to control MS symptoms, and escalating to more potent therapies in the face of continued disease symptoms. An "EHT approach" involves giving a drug that has a higher likelihood of working but that has more risks. Please contact our team for more information about this study and the approaches available in it. Study takes place at UBMD Neurology,
1001 Main Street, 4th Floor, Buffalo, NY 14203.
To determine whether an EHT approach to DMT, defined as use of one of four monoclonal antibodies (alemtuzumab, natalizumab, rituximab, or ocrelizumab) as first-line therapy, is more effective than an escalation of treatment approach in reducing normalized whole brain volume loss measured using MRI in PwRRMS from Baseline to Month 36.
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Adults ages 18+.
Diagnosed with Multiple Sclerosis (MS).
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email email@example.com and someone will assist you.